News Sentiment

IMMX sentiment intelligence

Immix Biopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 11.11 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.4% over one week, +31.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 7.4% Price confirming higher
Trend fit Trend active 31.5% over four weeks
Fair value 194.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 36
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 9
Stock Titan 9
TradingKey 5
MT Newswires 3
simplywall.st 3
Quiver Quantitative 2
www.timothysykes.com 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 18
Analyst action 10
Regulatory and legal 1
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
www.timothysykes.com Direct company coverage

Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock price information and charts for Immix Biopharma Inc. (IMMX), showing its current price of $10.52, a decrease of $0.16 (-1.50%). It also indicates that there are currently no analyst ratings or earnings information available for the company. The page

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 22:39
Source
www.timothysykes.com
Finimize Direct company coverage

Immix Biopharma’s Big Run Rests On Early CAR-T Data

Immix Biopharma (NASDAQ: IMMX) has experienced a significant 310% stock jump over the past year, driven by positive early data from its NXC-201 CAR-T therapy for AL amyloidosis and multiple myeloma. The company's valuation is highly reliant on clinical advancements, regulatory de

Tone
Positive 63/100
Event
Regulatory and legal
Published
12 Jul 2026 18:41
Source
Finimize
TradingView Direct company coverage

Enterprise value to revenue forward of Immix Biopharma, Inc. – NASDAQ:IMMX

This article provides financial information for Immix Biopharma, Inc. (NASDAQ: IMMX), specifically focusing on its enterprise value to forward revenue. It appears to be an entry from a financial data platform, presenting a metric and linking to further financial and company detai

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 12:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Immix Biopharma, Inc. – NASDAQ:IMMX

The article displays the "Price to book forward" for Immix Biopharma, Inc. (NASDAQ: IMMX). It is presented as a financial data point within the TradingView platform, indicating a specific period, value, and percentage change.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 12:13
Source
TradingView
TradingView Direct company coverage

Immix Biopharma, Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Immix Biopharma, Inc.'s SEC filings and other corporate documents, including earnings reports and corporate presentations, from 2021 to 2026. It highlights key financial performance updates, clinical progress for NXC-201, and details

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 03:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Immix Biopharma, Inc. – NASDAQ:IMMX

This article provides the "Price to sales forward" metric for Immix Biopharma, Inc. (NASDAQ: IMMX), noting that the market was closed with no trades when this information was accessed. It highlights financial data presented on TradingView without specifying the actual value.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 15:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Immix Biopharma, Inc. – NASDAQ:IMMX

This article displays the "Price to earnings forward" value for Immix Biopharma, Inc. (NASDAQ: IMMX) on the TradingView platform. It presents financial data for the company and is part of a larger market analysis tool.

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 10:09
Source
TradingView
TradingView Direct company coverage

Immix Biopharma, Inc. Actuals & Estimates (NASDAQ:IMMX)

This article provides details on Immix Biopharma, Inc. (NASDAQ: IMMX) stock performance, analyst estimates, and financial data. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, alongside other financia

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

IMMX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Immix Biopharma, Inc. (IMMX) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, financial statistics like market capitalization and earnings, and information on future earni

Tone
Positive 67/100
Event
Analyst action
Published
25 Jun 2026 14:10
Source
TradingView
Investing.com Nigeria Direct company coverage

BofA initiates Immix Biopharma stock with buy rating on AL amyloidosis drug

BofA Securities has initiated coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and a $27 price target, citing the potential of its NXC201 drug for AL amyloidosis. The drug has shown promising early data with a 95% complete response rate and a favorable safety profile.

Tone
Positive 80/100
Event
Analyst action
Published
19 Jun 2026 10:39
Source
Investing.com Nigeria
Benzinga Direct company coverage

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

Bank of America Securities initiated coverage on Immix Biopharma (NASDAQ: IMMX) with a Buy rating and a $27 price target, citing strong clinical data for NXC-201 in AL amyloidosis. The analyst models worldwide risk-adjusted peak sales of $963 million for NXC-201, which has shown

Tone
Positive 65/100
Event
Analyst action
Published
18 Jun 2026 17:09
Source
Benzinga
Market source Direct company coverage

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

Wall Street analysts project that Immix Biopharma (IMMX) could see a 113.58% surge, with a mean price target of $19.5. While consensus price targets should be treated with skepticism due to analysts' potential biases, the recent positive trend in earnings estimate revisions and a

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 13:55
Source
Market source
TradingView Direct company coverage

Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside

Immix Biopharma, Inc. (IMMX) has seen its average price target raised to $19.79 from $18.58 by 7 analysts, with forecasts ranging from $14.50 to $27.00 per share. This updated target implies a potential upside of approximately 117% based on the June 17 closing price. The consensu

Tone
Positive 91/100
Event
Analyst action
Published
18 Jun 2026 13:09
Source
TradingView
TradingKey Direct company coverage

Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Immix Biopharma Inc (IMMX), highlighting analyst ratings, target prices, and past EPS performance. Five analysts currently rate IMMX as a "Buy" with a target price of $21.00, suggesting a 130.01% upside. The report also lists peer co

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 08:40
Source
TradingKey
TradingKey Direct company coverage

Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Immix Biopharma Inc (IMMX) focusing on its dividend history and stock splits. The data presented indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. The article also in

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 08:09
Source
TradingKey
TradingKey Direct company coverage

Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on Immix Biopharma Inc (IMMX) and its revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides basic stock information

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 01:09
Source
TradingKey
GuruFocus Direct company coverage

IMMX Initiates Coverage On LifeSci Capital -- Rating at Outperfo

LifeSci Capital initiated coverage on Immix Biopharma (IMMX) with an "Outperform" rating and a $19.00 price target, suggesting significant upside from its current trading price of $9.31. Despite a low GF Score™ of 30/100, indicating weaknesses in profitability and growth, IMMX bo

Tone
Positive 68/100
Event
Analyst action
Published
17 Jun 2026 20:09
Source
GuruFocus
TradingKey Direct company coverage

Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis

This article provides a brief overview of Immix Biopharma Inc's (IMMX) stock performance and valuation metrics. It notes that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The article also includes current stock price inform

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 16:09
Source
TradingKey
TradingKey Direct company coverage

Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Immix Biopharma Inc (IMMX), analyzing its volatility, financial risk, and investment risk. It details various metrics such as Beta, VaR, Maximum Drawdown, Volatility, and Return-to-Drawdown Ratio over different periods. The purpose is t

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 15:41
Source
TradingKey
Finviz Direct company coverage

IMMX - Immix Biopharma Inc Stock Price and Quote

This page provides a comprehensive overview of Immix Biopharma Inc. (IMMX) stock, including its latest stock price, financial data, performance metrics, and recent news and analyst ratings. It also details insider transactions, highlighting purchases by the CEO and CFO, and lists

Tone
Positive 73/100
Event
Analyst action
Published
07 Jun 2026 04:09
Source
Finviz
Stock Titan Direct company coverage

Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX)

Janus Henderson Group plc has filed an amended Schedule 13G/A, reporting beneficial ownership of 9,090,732 shares, or 13.0% of Immix Biopharma, Inc. (IMMX). The filing indicates that Janus Henderson's Asset Managers exercise shared voting and dispositive power over these shares,

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 16:40
Source
Stock Titan
Stock Titan Direct company coverage

Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options

Immix Biopharma director Nancy T. Chang received equity awards totaling 6,250 restricted stock units (RSUs) and options for 12,500 shares. These awards, granted under the 2021 Equity Incentive Plan, are subject to vesting schedules tied to continued service and the company's 2027

Tone
Neutral 50/100
Event
Market update
Published
30 May 2026 12:10
Source
Stock Titan
Stock Titan Direct company coverage

Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78

Immix Biopharma's CFO and President, Morris Gabriel S, was granted 500,000 stock options with an exercise price of $8.78 per share, expiring on May 22, 2036. The options vest in 48 equal monthly installments, linking the executive's ownership to continued service. This grant is c

Tone
Neutral 50/100
Event
Market update
Published
30 May 2026 12:08
Source
Stock Titan
Stock Titan Direct company coverage

Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option

Immix Biopharma director Carey Ng received 6,250 restricted stock units (RSUs) and a stock option for 12,500 shares. The RSUs will vest on the earlier of one year from the grant date or the 2027 annual stockholders' meeting, while the stock option vests in monthly installments ov

Tone
Neutral 50/100
Event
Market update
Published
30 May 2026 12:08
Source
Stock Titan